Colorectal Cancer Screening Guideline Update – May 30, 2018
On May 30, 2018, the American Cancer Society released a new colorectal cancer screening guideline, published in CA: A Cancer Journal for Clinicians. The new guideline recommends that adults at average risk for colorectal cancer start regular screening at age 45. The guideline was changed, based in part, on new data showing rates of colorectal cancer are increasing in younger populations. As a result, the American Cancer Society updated the guideline to save more lives by finding colorectal cancer early, when treatment is more likely to be successful and by detecting and removing polyps, which contributes to the prevention of colorectal cancer.
This webinar assists NCCRT members and 80% partners by answering common questions, reviewing the evidence-base behind the guideline, and discussing how it will apply in a clinical setting.
Speakers:
- Rich Wender, MD, Chief Cancer Control Officer, ACS, National Colorectal Cancer Roundtable (NCCRT) Chair
- Robert Smith, PhD, VP, Cancer Screening, ACS, NCCRT Co-Chair
- Durado Brooks, MD, MPH, VP of Cancer Control Interventions, NCCRT Steering Committee/Co-Chair Community Health Center Task Group
- Caroline Powers, Federal Affairs Director, ACS CAN
Additional Resources:
- Video message from Dr. Richard Wender
- Issue Brief and FAQ for NCCRT Members and 80% Pledger Signers
- ACS Press Release
Explore More

Blue Star Conversation: April 15, 2025
This Blue Star Conversation covered, "Modeling the Impact of Colorectal Cancer Screening and Timely Follow-Up Colonoscopy: Recent Data from the Cancer Intervention and Surveillance Modeling Network (CISNET)"

ACS Webinar: Cancer Prevention and Screening for Community Health Centers
This webinar focused on health centers and covered the current state of colorectal cancer, the urgent need for screening patients age 45-55, and a review of tools and resources available.

Clinician’s Reference: Stool-Based Tests for Colorectal Cancer Screening
This revised resource is designed to introduce (or reintroduce) clinicians to the value of stool-based testing for colorectal cancer.